See what questions
a doctor would ask.
A new drug by Schering is set to receive FDA approval upon the provision of additional information. The drug is called Bonefos and it claims to stop breast cancer metastasizing to the bones. It reduces pain and makes bones stronger by restoring the balance between destruction of old bone cells and replacement of new ones. Once breast cancer metastasizes to the bones, the life expectancy is about two years. The drug's approval process was sped up when studies showed that the drug cut breast-cancer deaths by 23% compared to a placebo in a study involving 1,069 subjects. The drug is already approved by 79 countries for use in treatment bone loss following chemotherapy in premenopausal women and increases bone density in postmenopausal breast cancer patients. It also treats excess calcium in the blood. The drug's advantage over competitors is that it is administered orally or intravenously compared to its rivals which can only be administered intravenously. Thus it is a more viable long-term treatment option.
Source: summary of medical news story as reported by Bloomberg
About: New breast cancer drug faces imminent approval
Date: 7 January 2005
http:/ This summary article refers to the following medical categories:
Related Medical Topics
More News Topics
This summary article refers to the following medical categories:
Search Specialists by State and City